Page 1,069«..1020..1,0681,0691,0701,071..1,0801,090..»

CSIR forms five verticals to combat COVID-19 – The Hindu

Posted: April 9, 2020 at 4:50 am

Council of Scientific & Industrial Research (CSIR) has galvanised all its labs into action to battle COVID-19 in the last few weeks, with the Director-General Shekhar C. Mande, forming five verticals to coordinate various research activities into drugs, vaccine, testing, sanitisers, hospital equipment and the likes.

The digital and molecular surveillance is led by its directors Dr. Anurag Agarwal of Institute of Genomics & Integrated Biology (IGIB), rapid and economical diagnosis by Dr. Rakesh Mishra of Centre for Cellular & Molecular Biology (CCMB), development of new drugs/re-purposing of drugs by Dr. S Chandrashekhar of Indian Institute of Chemical Technology (IICT), hospital assistive devices by Dr. Jitendra J. Jadhav of National Aerospace Laboratories, personnel protective equipment and supply chain & logistics by Dr. Anjan Ray of Indian Institute of Petroleum.

A CSIR Strategic Group (CSG) has also been constituted with a video zoom meeting organised every day and presided over by the DG to review the progress made by these verticals. Any lab or scientist willing to contribute to any of the five verticals can write to the lead directors mentioned above. The Director of Indian Institute of Integrative Medicine (IIIM), Dr. Ram A. Vishwakarma, has been made the overall coordinator.

Sequencing of coronovirus is being done at IGIB and CCMB including that of the host and virus RNA. Incidentally, the former has developed a paper-based diagnostic test while CCMB is setting up viral cultures for testing of drugs and making a vaccine, said informed scientific sources, privy to the meeting of top heads.

CSIR DG has mentioned the contribution of Dr. Debojyoti Chakraborti IGIB, for developing crispr/case-based paper diagnostics, Dr. Anthony Adlagatta of IICT for producing reverse transcriptase in large quantities, CCMB scientists for developing cell line and virus culture, sanitisers by IICT, Indian Institute of Toxicology Research (IITR), Central Electro Chemical Research Institute CECRI), North East Institute of Science and Technology (NEIST), etc., food packets by Central Food Technological Research Insitute (CFTRI), and Institute of Himalayan Bioresource Technology (IHBT).

Dr. Mande informed during the interaction that a platform for open innovation will be developed and hosted at the CSIR headquarters and a partnership has already been formed with the Ministry of Ayush for development of four botanicals/drugs.

CSIR labs are already working with private sector giants like Reliance for PPEs, diagnostics; Tatas for hospital assistive devices; Intel & TCS for digital surveillance; CIpla for repurposed drugs; Cadila for coronavirus therapy; Bharat Biotech for inactivated vaccine development; BHEL for electrostatic spray and ventilator; BEL for thermometer and Oxygen enrichment unit, etc,

Three of its institutes CCMB, IGIB and IIIM have been allowed to take up Covid-19 testing and other eight other CSIR labs too are ready to take it up once regulatory approvals come, said informed scientific sources.

You have reached your limit for free articles this month.

Register to The Hindu for free and get unlimited access for 30 days.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Originally posted here:
CSIR forms five verticals to combat COVID-19 - The Hindu

Posted in Integrative Medicine | Comments Off on CSIR forms five verticals to combat COVID-19 – The Hindu

The Growing Prison Pandemic Wasn’t Inevitable, and It’s Not Too Late to Fight It – brennancenter.org

Posted: April 9, 2020 at 4:49 am

The Covid-19 outbreaksnow surgingthrough many of the nations prisons and jails werent just predictable, they were predicted. And not just by theprisoners themselvesand theirfamily membersinincreasingly desperate tonesoverthe past monthbut also by some sheriffs andjailersandcorrections officialsand theirunion representatives. And not just by those behind bars but bylawyersanddoctorsandcriminal justice advocatesand professors,hundreds of them, in every nook and cranny of the country, all of whom understood how dangerous and deadly the pandemic would be once itfound its wayinto cramped, dirty, overcrowded cells.

These personalcries for help,these warnings, thesepersonal essays from prisons, these reasoned arguments to release vulnerable prisoners especially those whose sentences are about to expire and those in pretrial detention accused of nonviolent offenses sounded everywhere. And they were all a variation of the same theme: that prisons and jailswere obvious breeding grounds for the virus, that it could not be contained behind bars, that theinevitable outbreakswouldnt just take or endanger the lives of prisoners but would kill prison staff and their extended families; in other words, that preventing the pandemic in prison would save lives on the outside.

To theireternal credit, some officials have heard the call anddone the right thing. Thousands of men and women were released fromprisonsand jailsover the past monthand many more should be released soon. But in too many other places,politiciansand prosecutors waitedfor the virus to enter their facilitiesbeforeacting to save prisoners. And in some places eventhe spread of the virusand its obvious threat to everyone in or near a prisonhasnt been enoughto convincesome officialsthat there aremore important public safety interestsat stake than continuing to imprison at-risk people in the name of justice.

Like so much else about Americas criminal justice systems, a prisoners fate amid the pandemic is an arbitrary affair, largely determined by jurisdiction. If you were released from confinement in the past month its largely because you happened to have an enlightened jailer,or compassionate judge, or broad-minded prosecutor, or because you had particularlyferocious advocatesfighting for you. Or maybe the laws of your state happened to have a little more ambiguity. Or maybe you had a governor willing to say, on the record, that public safety in these circumstances includes the idea of fewer prisoners.

Even still, there are no guarantees. Officials at the Cook County Jail in Illinois, for example, reduced their population by 16 percent in the last month to try to help bend the curve but still are suffering from a terrible outbreak. As of this weekend, nearly300 prisoners and staff have tested positivethere,nearly 4 percent of the entire states numberof confirmed cases. How much worse would the outbreak have been there had that 16 percent remained behind bars? How many fewer cases of the virus will stem from the social distancing these lucky men and women now can practice?

There is a growing outbreak, too, at the jail in Washington, DC, wherefour more prisoners were confirmed positiveover the weekend. There,as attorney Greg Lipper pointed out, lawyers for the Districts attorney general opposed the release of prisoners by arguing, incredibly, that they had not met their burden of proof. Although complete social distancing and isolation is not possible in DOC facilities,the lawyers wrote, plaintiffs have not shown that the risk posed by DOCs practices raises plaintiffs risk of exposure substantially over the risk experienced by the outside community. Fewer sentences in the annals of American law deserve more opprobrium than that one.

The federal response was equallytardyand tragic. As my colleagues at The Marshall Projectreported last week, the chief public health official at the Bureau of Prisons ordered a staff member at FCI Oakdale, in Louisiana, to return to work behind bars even though he had been exposed to those who had tested positive for Covid-19. Not only did this advice contradict the guidance offered by the Centers for Disease Control, it also came at a time when Justice Department officials were downplaying the potential consequences of a prison outbreak, with federal prosecutors going so far as to write briefsopposingreasonable release requests.

Today? At leasteight federal prisoners have died from Covid-19and over 300 other prisoners and staff have tested positive, and there is no way to tell how far the coronavirus has spread into the families of the prison guards and others who work there. FCI Oakdale is not alone. There isalso a COVID-19outbreak at the low-security federal prison in Danbury, Connecticut. The Justice Department waited until these outbreaks occurred andthenswiftly ordered the release of prisoners there. We will never know how many lives are lost, behind bars and beyond them,because of these inexcusable delays. Wedont even know for surethat the Bureau of Prisons will zealously implement the new plan.

These corrections officials and sheriffs and judges and prosecutors and legislators didnt have to wait until it was too lateto protect prisoners.But they waited anyway. They waited to release prisoners who had not been convicted. They waited to release prisoners who were slated for release within 60 or 90 days. They argued that elderly prisoners, if released, would start a crime wave. They argued that carrying out duly imposed sentences were more important than saving lives. They argued they had it all under control evenwhen the rest of usknew they didnt. And if theydidrelease some prisonersit was a paltry few. Far too few.

Its negligence at best,deliberate indifference at worst. Robert Ferguson, the author and professor, years ago described the reasons why America has always beenso spectacularly harsh in its treatment of prisoners. Never hasthat theory been proven more clearlythan it has been in the past month. Except the cruelty shown the prisoners who have been kept locked up as the virus spreads doesnt just end with them. It attaches to the staff who guard them, and to their families, their lawyers, and to everyone who interacts with them. All of these non-prisoners, as well as those behind bars, may soon suffer from the virus, a form of retributive justice neither retributive nor just.

The views expressed are the authors own and not necessarily those of the Brennan Center.

Read this article:
The Growing Prison Pandemic Wasn't Inevitable, and It's Not Too Late to Fight It - brennancenter.org

Posted in Connecticut Stem Cells | Comments Off on The Growing Prison Pandemic Wasn’t Inevitable, and It’s Not Too Late to Fight It – brennancenter.org

Jeffrey Epstein and the Hideous Strength of Transhumanism – National Catholic Register

Posted: April 9, 2020 at 4:47 am

Transhumanism rides roughshod over the dignity of the human person in its quest for the technologically created superman.

The sordid life of Jeffrey Epstein serves to highlight the decadence of the deplorable epoch in which we find ourselves, as do the suspicious circumstances surrounding his death. The web of vice and viciousness that he had spun was widespread, serving to entrap not only underage girls but also the rich and famous who preyed upon them. Using the allure of underage sex to lure his wealthy associates into his web, Epstein secretly filmed them in the act of sexually abusing minors, thereby turning his associates into his blackmail victims.

Epstein seems to have believed that the powerful people whom hed entrapped in his insurance policy would have a vested interest in keeping him safe from the law, a strategy which worked for a while. In 2008, Epstein was convicted in Florida of sexually abusing a 14-year-old girl, receiving a scandalously light sentence, but due to a plea deal he was not charged with sexually abusing 35 other girls whom federal officials identified as having been abused by him.

After a further 10 years in which Epstein masterminded the trafficking of young girls to satisfy the pornographic and pedophilic appetites of his powerful network of friends, he was finally charged in July of last year with the sex trafficking of minors in Florida and New York. A month later, he was found dead in his jail cell. Although the medical examiner originally recorded the death as being a case of suicide, there are so many anomalies and mysteries surrounding the circumstances of Epsteins death that many people agree with Epsteins lawyers that the death could not have been suicide. One thing that is certain is that Epsteins death removed the possibility of pursuing criminal charges. There would be no trial, and therefore no exposing of Epsteins powerful associates by their victims in a court of law. Seen in this light, or in the shadow of this possible cover-up, it is tempting to see Epsteins insurance policy as his death warrant. He was too dangerous to be allowed to live when the lives of so many others depended on his timely death. It is no wonder that Epstein didnt kill himself has become a hugely popular meme, nor that HBO, Sony TV and Lifetime are planning to produce dramatic portrayals of Epsteins life and death.

One aspect of Epsteins life which is unlikely to be the focus of any TV drama is his obsession with transhumanism. For those who know little about this relatively recent phenomenon, transhumanism is usually defined as the movement in philosophy which advocates the transformation of humanity through the development of technologies which will re-shape humans intellectually and physiologically so that they transcend or supersede what is now considered human. At the prideful heart of this movement is a disdain for all that is authentically human and a sordid desire to replace human frailty with superhuman or transhuman strength.

Transhumanism rides roughshod over the dignity of the human person in its quest for the technologically created superman. Its spirit was encapsulated by David Bowie in the lyrics of one of his songs: Homo sapiens have outgrown their use Gotta make way for the homo superior.

Most of Epsteins so-called philanthropy was directed to the financing and promotion of transhumanism. The Jeffrey Epstein VI Foundation pledged $30 million to Harvard University to establish the Program for Evolutionary Dynamics and also bankrolled the OpenCog project which develops software designed to give rise to human-equivalent artificial general intelligence. Apart from his support for the cybernetic approach to transhumanism, Epstein was also fascinated with the possibility of creating the superman via the path of eugenics. He hoped to help in a practical way with plans to seed the human race with his DNA by impregnating up to 20 women at a time at a proposed baby ranch at his compound in New Mexico. He also supported the pseudo-science of cryonics which freezes human corpses and severed heads in the hope that technological advances will eventually make it possible to resurrect the dead. He had planned to have his own head and penis preserved in this way.

In addition to his bizarre association with the wilder fringes of technological atheism, Epstein also co-organized a conference with his friend, the militant atheist Al Seckel, who is known, amongst other things, for his creation of the so-called Darwin Fish symbol, seen on bumper stickers and elsewhere, which depicts Darwins superior evolutionary fish eating the ichthys symbol or Jesus fish of the Christians. Seckel fled California after his life of deception and fraud began to catch up with him and he was found at the foot of a cliff in France having apparently fallen to his death. Nobody seems to know whether he slipped, jumped or was pushed.

Apart from his unhealthy interest in atheistic scientism, Jeffrey Epstein was also a major figure amongst the globalist elite. According to his lawyer, Gerald B. Lefcourt, he was part of the original group that conceived the Clinton Global Initiative which works to force the poor countries of the world to conform to the values of the culture of death. Even more ominously, Epstein was a member of the Trilateral Commission and the Council on Foreign Relations, two of the key institutions responsible for fostering and engineering the globalist grip on the worlds resources.

As we ponder the sordid and squalid world of Jeffrey Epstein and his associates, we cant help but see his life as a cautionary tale, the moral of which is all too obvious. It shows that pride precedes a fall and that it preys on the weak and the innocent. It shows that those who think they are better than their neighbors become worse than their neighbors. It shows how Nietzsches Untermensch morphs into Hitlers Master Race and thence to the Transhuman Monster. It shows that those who admire the Superman become subhuman. It also shows that the subhuman is not bestial but demonic. It shows that those who believe that they are beyond good and evil become the most evil monsters of all.

Those of us who have been nurtured on cautionary tales such as Mary Shelleys Frankenstein or C. S. Lewiss That Hideous Strength will know that fiction often prefigures reality. We will see that the real-life figure of Jeffrey Epstein is a latter-day Viktor Frankenstein, reaping destruction with his contempt for his fellow man and his faith in the power of scientism to deliver immortality to those who serve it. We will also see that the transhumanism which Epstein financed is a mirror image of the demonic scientism of the secretive National Institute of Coordinated Experiments in Lewis prophetic novel. We will also be grimly amused by the fact that the leader of the demonic scientistic forces in Lewis tale is a severed head which has apparently been brought back to life.

And there is one final lesson that the pathetic life of Jeffrey Epstein teaches us. It shows us that the adage that the devil looks after his own is not true. It is in fact a lie told by the devil himself. The devil hates his disciples as much as he hates the disciples of Christ; once he has had his way with them, he disposes of them with callous and casual indifference, much as Jeffrey Epstein disposed of those whom he sexually abused.

This essay first appeared in Crisis Magazine and is republished with permission.

See the rest here:
Jeffrey Epstein and the Hideous Strength of Transhumanism - National Catholic Register

Posted in Transhumanism | Comments Off on Jeffrey Epstein and the Hideous Strength of Transhumanism – National Catholic Register

Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development – Business Wire

Posted: April 8, 2020 at 10:45 am

VANCOUVER, British Columbia--(BUSINESS WIRE)--Products made by Vancouvers STEMCELL Technologies are now being used in over 30 COVID-19 studies worldwide. These studies are focusing on areas ranging from diagnostics and treatments to vaccine development and future prevention. STEMCELL is playing a crucial role in COVID-19 research by providing cutting-edge laboratory tools and reagents as well as through close collaborations with scientists. This will ultimately accelerate the pace of discovery and hopefully lead to a rapid resolution to the global pandemic.

At STEMCELL, we have a team of world-class scientists who have dedicated their careers to developing superior cell culture and cell isolation systems required to study devastating diseases, said Dr. Allen Eaves, STEMCELLs Founder, President, and CEO. It is always incredibly rewarding to see their hard work and expertise put to use. Every day were learning about new ways our customers are using our products to research solutions for the COVID-19 pandemic, and were actively working to support these researchers in any way we can.

STEMCELL is the global industry expert in developing systems for culturing human organoids, which are three-dimensional clusters of cells that closely resemble the biology of human organs. STEMCELL has partnered with an international team including Dr. Josef Penninger at the University of British Columbia, along with Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto, and Ali Mirazimis infectious biology team in Sweden. The group used STEMCELLs organoid systems in a study that examined how SARS-CoV-2 infects patients. Their findings, recently published in the top scientific journal Cell, provide insight into a potential treatment capable of stopping early infection of the novel coronavirus.

Human organoids enable us to better understand the pathology of this disease and to rapidly reach a therapeutic breakthrough. This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conders gastrointestinal group at STEMCELL Technologies, who have all been working tirelessly day and night for weeks, said Dr. Penninger.

Life science researchers and clinical labs also depend on STEMCELLs specialized cell isolation tools and instruments to extract the white blood cells responsible for immune responses from blood samples. Dr. James Crowe at the Vanderbilt Vaccine Center in Nashville, Tennessee is using a custom version of STEMCELLs EasySep system to isolate specific immune cells from the blood of COVID-19 survivors. Their goal is to rapidly develop antibody treatments and vaccines. This research group has used the same system to identify potential treatments for other viruses, including Ebola, chikungunya, HIV, dengue, norovirus, and respiratory syncytial virus.

STEMCELL listened to us when we came to them asking for custom tools to isolate the specific immune cells were working with from COVID-19 patients, said Dr. Crowe. We were able to integrate the new products and protocols into our research. In turn, we hand information about these products back to STEMCELL so that they can make it available to other labs. Its been a productive collaboration.

STEMCELL recently reported that researchers at Chinas Centre for Disease Control (CDC) successfully used STEMCELLs lung cell culture product, PneumaCultTM, to grow human lung airway cells and quickly obtain the viruss gene sequence, drastically shortening the path to vaccine development. Additionally, an international team including long-time STEMCELL collaborator Dr. Franois Jean at the University of British Columbia, an expert in antiviral drug discovery and emerging human viruses, is using STEMCELLs lung tissue culture system in a recently-funded study to develop and evaluate candidate therapeutics for COVID-19.

Solving medical challenges requires experts in science and medicine to work together with efficiency and accuracy, says Dr. Eaves. STEMCELL is proud to be a crucial component of this network by providing innovative tools, services, and expertise needed by our colleagues in research labs and clinical settings globally.

In addition to supporting rapid and groundbreaking developments for COVID-19 research, STEMCELLs products have been used successfully to study many other devastating viruses. This includes the use of PneumaCult to study respiratory viruses such as various coronaviruses, parvovirus, rhinovirus, respiratory syncytial virus, and influenza. Scientists have also successfully modeled microcephaly caused by Zika virus and cytomegalovirus using STEMCELLs BrainPhys and other products for neuroscience research. Similarly, STEMCELLs IntestiCult was used to study viruses targeting the intestinal system, including enteric coronavirus and norovirus. Finally, STEMCELLs EasySep reagents and RoboSep instrument have been central to studies of the immune response to viruses including HIV, Ebola, and dengue viruses.

About STEMCELL Technologies

STEMCELL Technologies is Canadas largest biotechnology company, with over 1,500 employees and year-on-year growth of approximately 20% for the last 26 years. Based in Vancouver, STEMCELL supports life sciences research around the world with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists advancing the stem cell, immunology, cancer, regenerative medicine, microbiology, and cellular therapy fields. Find more information at http://www.stemcell.com.

Continued here:
Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development - Business Wire

Posted in Stem Cell Research | Comments Off on Canadian Company STEMCELL Technologies Is an Essential Industry Partner for COVID-19 Research and Vaccine Development – Business Wire

India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 – IndianWeb2.com

Posted: April 8, 2020 at 10:45 am

Stempeutics Research, a group company of Manipal Education and Medical Group (MEMG), announced today that it has partnered with Global Consortium of cell therapy companies seeking European Commission Funding to Fight Against Corona! (FAC!). Under this partnership, Stempeutics will export its stem cell product Stempeucel (subject to regulatory approvals) for treating critically ill COVID-19 patients with lung disease. First the product will be clinically tested and upon successful outcomes, it intends to export the product on a regular basis. In this connection it is signing up an alliance with Educell Ltd, Slovenia.

Currently, no specific drugs or vaccines are available to cure the patients with COVID-19 infection. Mortality in COVID-19 infected patients with the inflammatory lung condition ARDS (Acute Respiratory Distress Syndrome)is reported to approach 50%, and is associated with older age, co-morbidities such as diabetes, cardiovascular disease, COPD (chronic obstructive pulmonary disease), higher disease severity, and elevated markers of inflammation. Current therapeutic interventions (with the exception of ventilators/respirators which are in very short supply) do not appear to be improving in-hospital survival. Hence, there is a large unmet need for a safe and effective treatment for COVID-19 infected patients, especially in severe cases. A promising new therapy for the ARDS, the terminal stage of COVID-19, using MSCs can quickly (2-4 days) reduce inflammation of the lung tissue, and allow patients to more quickly come off of the ventilatory support and hopefully fully recover with less significant lung damage.

Stempeucel is an allogeneic, off the shelf, pooled mesenchymal stromal cells having anti- inflammatory and immune-modulatory properties which prevents the over activation of the immune system. Stempeucel product exhibits a wide range of potent therapeutic properties. The product exhibits potent immunomodulatory and anti-inflammatory properties which could help in reducing the inflammation caused due to the cytokine storm elicited by the bodys immune cells in response to SARS-CoV-2 (COVID-19) related infection in the lungs. Also, the growth factor, Angiopoietin-1 (Ang-1) is effective in reducing alveolar epithelium permeability in the lung. Hence it is envisaged, Stempeucel will reduce the fatal symptoms of COVID 19 induced pneumonia and its progression to ARDS.

Commenting on this initiative, Dr. Miomir Knezevic, Leader of the Global Consortium and Founder of Educell said, We are happy to partner with Stempeutics since its product Stempeucel is already designated as an ATMP1 in Europe and also Stempeucel technology has been patented in many countries in Europe. Stempeutics manufacturing process is scalable and the product is affordable which are key to meet the demands of COVID-19 patients

Mr. BN Manohar, CEO of Stempeutics said, From the clinical data using Stempeucel in different clinical trials in other indications it may be postulated that Stempeucel has the potential capability for treating COVID-19 infection. Together with the safety profile observed from DCGI approved clinical trials involving more than 350 patients injected with Stempeucel by different routes of injection, this therapy may help in mitigating the lung tissue damaging effects of COVID-19 infection.

Dr. Stephen Minger, Scientific Advisor for the Global Consortium and ex Global Director of R&D, Cell Technologies GE Healthcare added The most severely affected CV-2 infected patients will often go on to develop ARDS which necessitates assisted ventilation to preserve breathing and lung function. Moreover, many ARDS patients will also experience an acute but severe life-threatening inflammatory response (cytokine storm) which can result in long-term damage to lung tissue and lung function. Treating ARDS patients with allogeneic expanded bone marrow derived MSCs could alleviate and ameliorate lung inflammation and compromised lung function and significantly reduce the time required for patients to be ventilated.

Dr. Raviraja N S, Sr. Director Business Development and Innovation, Stempeutics, said, Given the severe shortage of ventilators in the world, and the high mortality rate of patients who develop ARDS (approx. 50%), the clinical use of MSCs in COVID-19 ADRS patients could drastically impact on the healthcare burden currently occurring due to very large patient numbers, limited equipment and overworked medical personnel.

Mr. B N Manohar MD & CEO, Stempeutics Research

Manohar is the MD & CEO of Stempeutics Research a leading stem cell research and product development company in India. He earned his B.E. degree in Electronics & Communication from REC Trichy in 1977. Post that he did M.E. in Computer Science from College of Engineering, Guindy. Manohar has transformed Stempeutics a life science start-up from R&D to Commercialization stage with Global recognition. Stempeutics has developed an innovative drug called Stempeucel for addressing major unmet medical needs in India and Globally.

This drug developed by an Indian company has received many Global Recognitions. Fourteen countries including US & Japan has granted patent for the novelty and inventiveness of the drug. Europe has recognized this drug by granting Advanced Therapy Medicinal Product classification and Orphan Drug Designation. Recently it became the FIRST stem cell product to be approved by DCGI for conditional marketing for treating patients suffering from life threatening disease call Buergers Disease. Stempeutics has put India on the World map of Regenerative Medicine. Under Manohars leadership Stempeutics has been recognized as Indias hottest start-ups by Business Today in 2008 and Karnataka Government bestowed Emerging Company of the Year award in 2011 and 2013. In 2017 Manohar was awarded Biotechnologist of the Year award by Wockhardt Foundation, India. He raised US$ 10M in 2009 by establishing business alliance with major pharma company Cipla. Recently Stempeutics has tied up with Alkem Labs for Osteoarthritis indication. Prior to Joining Manipal Group, Manohar has had 12 years successful stints at Wipro GE Medical Systems. At GE Medical he has handled multiple senior assignments including Vice President Customer Service where he received GE Asia Service Award for highest revenue growth in 1998. Currently Manohar serves in the Boards of Stempeutics and MentisSoft.

Like this content? Sign up for our daily newsletter to get latest updates.

Read the original post:
India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 - IndianWeb2.com

Posted in Stem Cell Research | Comments Off on India Based Stem Cell Research Firm To Test Its Stem Cell Product For Acute Respiratory Disease Syndrome (ARDS) COVID-19 – IndianWeb2.com

COVID-19 Impact on Stem Cell Banking Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 – Science…

Posted: April 8, 2020 at 10:45 am

Complete study of the global Stem Cell Banking market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Stem Cell Banking industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on Stem Cell Banking production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

Key companies operating in the global Stem Cell Banking market include _, CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1637547/global-stem-cell-banking-market

Segmental Analysis

The report has classified the global Stem Cell Banking industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the Stem Cell Banking manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall Stem Cell Banking industry.

Global Stem Cell Banking Market Segment By Type:

Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Global Stem Cell Banking Market Segment By Application:

, Diseases Therapy, Healthcare

Competitive Landscape

It is important for every market participant to be familiar with the competitive scenario in the global Stem Cell Banking industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key companies operating in the global Stem Cell Banking market include _, CCBC, CBR, ViaCord, Esperite, Vcanbio, Boyalife, LifeCell, Crioestaminal, RMS Regrow, Cordlife, PBKM FamiCord, cells4life, Beikebiotech, StemCyte, Cryo-cell, Cellsafe Biotech, PacifiCord, Americord, Krio, Familycord, Cryo Stemcell, Stemade Biotech

Key questions answered in the report:

Enquire Customization in The Report: https://www.qyresearch.com/customize-request/form/1637547/global-stem-cell-banking-market

TOC

1 Market Overview of Stem Cell Banking1.1 Stem Cell Banking Market Overview1.1.1 Stem Cell Banking Product Scope1.1.2 Market Status and Outlook1.2 Global Stem Cell Banking Market Size Overview by Region 2015 VS 2020 VS 20261.3 Global Stem Cell Banking Market Size by Region (2015-2026)1.4 Global Stem Cell Banking Historic Market Size by Region (2015-2020)1.5 Global Stem Cell Banking Market Size Forecast by Region (2021-2026)1.6 Key Regions Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.1 North America Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.2 Europe Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.3 China Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.4 Rest of Asia Pacific Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.5 Latin America Stem Cell Banking Market Size YoY Growth (2015-2026)1.6.6 Middle East & Africa Stem Cell Banking Market Size YoY Growth (2015-2026)1.7 Coronavirus Disease 2019 (Covid-19): Stem Cell Banking Industry Impact1.7.1 How the Covid-19 is Affecting the Stem Cell Banking Industry1.7.1.1 Stem Cell Banking Business Impact Assessment Covid-191.7.1.2 Supply Chain Challenges1.7.1.3 COVID-19s Impact On Crude Oil and Refined Products1.7.2 Market Trends and Stem Cell Banking Potential Opportunities in the COVID-19 Landscape1.7.3 Measures / Proposal against Covid-191.7.3.1 Government Measures to Combat Covid-19 Impact1.7.3.2 Proposal for Stem Cell Banking Players to Combat Covid-19 Impact 2 Stem Cell Banking Market Overview by Type2.1 Global Stem Cell Banking Market Size by Type: 2015 VS 2020 VS 20262.2 Global Stem Cell Banking Historic Market Size by Type (2015-2020)2.3 Global Stem Cell Banking Forecasted Market Size by Type (2021-2026)2.4 Umbilical Cord Blood Stem Cell2.5 Embryonic Stem Cell2.6 Adult Stem Cell2.7 Other 3 Stem Cell Banking Market Overview by Type3.1 Global Stem Cell Banking Market Size by Application: 2015 VS 2020 VS 20263.2 Global Stem Cell Banking Historic Market Size by Application (2015-2020)3.3 Global Stem Cell Banking Forecasted Market Size by Application (2021-2026)3.4 Diseases Therapy3.5 Healthcare 4 Global Stem Cell Banking Competition Analysis by Players4.1 Global Stem Cell Banking Market Size (Million US$) by Players (2015-2020)4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Stem Cell Banking as of 2019)4.3 Date of Key Manufacturers Enter into Stem Cell Banking Market4.4 Global Top Players Stem Cell Banking Headquarters and Area Served4.5 Key Players Stem Cell Banking Product Solution and Service4.6 Competitive Status4.6.1 Stem Cell Banking Market Concentration Rate4.6.2 Mergers & Acquisitions, Expansion Plans 5 Company (Top Players) Profiles and Key Data5.1 CCBC5.1.1 CCBC Profile5.1.2 CCBC Main Business and Companys Total Revenue5.1.3 CCBC Products, Services and Solutions5.1.4 CCBC Revenue (US$ Million) (2015-2020)5.1.5 CCBC Recent Developments5.2 CBR5.2.1 CBR Profile5.2.2 CBR Main Business and Companys Total Revenue5.2.3 CBR Products, Services and Solutions5.2.4 CBR Revenue (US$ Million) (2015-2020)5.2.5 CBR Recent Developments5.3 ViaCord5.5.1 ViaCord Profile5.3.2 ViaCord Main Business and Companys Total Revenue5.3.3 ViaCord Products, Services and Solutions5.3.4 ViaCord Revenue (US$ Million) (2015-2020)5.3.5 Esperite Recent Developments5.4 Esperite5.4.1 Esperite Profile5.4.2 Esperite Main Business and Companys Total Revenue5.4.3 Esperite Products, Services and Solutions5.4.4 Esperite Revenue (US$ Million) (2015-2020)5.4.5 Esperite Recent Developments5.5 Vcanbio5.5.1 Vcanbio Profile5.5.2 Vcanbio Main Business and Companys Total Revenue5.5.3 Vcanbio Products, Services and Solutions5.5.4 Vcanbio Revenue (US$ Million) (2015-2020)5.5.5 Vcanbio Recent Developments5.6 Boyalife5.6.1 Boyalife Profile5.6.2 Boyalife Main Business and Companys Total Revenue5.6.3 Boyalife Products, Services and Solutions5.6.4 Boyalife Revenue (US$ Million) (2015-2020)5.6.5 Boyalife Recent Developments5.7 LifeCell5.7.1 LifeCell Profile5.7.2 LifeCell Main Business and Companys Total Revenue5.7.3 LifeCell Products, Services and Solutions5.7.4 LifeCell Revenue (US$ Million) (2015-2020)5.7.5 LifeCell Recent Developments5.8 Crioestaminal5.8.1 Crioestaminal Profile5.8.2 Crioestaminal Main Business and Companys Total Revenue5.8.3 Crioestaminal Products, Services and Solutions5.8.4 Crioestaminal Revenue (US$ Million) (2015-2020)5.8.5 Crioestaminal Recent Developments5.9 RMS Regrow5.9.1 RMS Regrow Profile5.9.2 RMS Regrow Main Business and Companys Total Revenue5.9.3 RMS Regrow Products, Services and Solutions5.9.4 RMS Regrow Revenue (US$ Million) (2015-2020)5.9.5 RMS Regrow Recent Developments5.10 Cordlife5.10.1 Cordlife Profile5.10.2 Cordlife Main Business and Companys Total Revenue5.10.3 Cordlife Products, Services and Solutions5.10.4 Cordlife Revenue (US$ Million) (2015-2020)5.10.5 Cordlife Recent Developments5.11 PBKM FamiCord5.11.1 PBKM FamiCord Profile5.11.2 PBKM FamiCord Main Business and Companys Total Revenue5.11.3 PBKM FamiCord Products, Services and Solutions5.11.4 PBKM FamiCord Revenue (US$ Million) (2015-2020)5.11.5 PBKM FamiCord Recent Developments5.12 cells4life5.12.1 cells4life Profile5.12.2 cells4life Main Business and Companys Total Revenue5.12.3 cells4life Products, Services and Solutions5.12.4 cells4life Revenue (US$ Million) (2015-2020)5.12.5 cells4life Recent Developments5.13 Beikebiotech5.13.1 Beikebiotech Profile5.13.2 Beikebiotech Main Business and Companys Total Revenue5.13.3 Beikebiotech Products, Services and Solutions5.13.4 Beikebiotech Revenue (US$ Million) (2015-2020)5.13.5 Beikebiotech Recent Developments5.14 StemCyte5.14.1 StemCyte Profile5.14.2 StemCyte Main Business and Companys Total Revenue5.14.3 StemCyte Products, Services and Solutions5.14.4 StemCyte Revenue (US$ Million) (2015-2020)5.14.5 StemCyte Recent Developments5.15 Cryo-cell5.15.1 Cryo-cell Profile5.15.2 Cryo-cell Main Business and Companys Total Revenue5.15.3 Cryo-cell Products, Services and Solutions5.15.4 Cryo-cell Revenue (US$ Million) (2015-2020)5.15.5 Cryo-cell Recent Developments5.16 Cellsafe Biotech5.16.1 Cellsafe Biotech Profile5.16.2 Cellsafe Biotech Main Business and Companys Total Revenue5.16.3 Cellsafe Biotech Products, Services and Solutions5.16.4 Cellsafe Biotech Revenue (US$ Million) (2015-2020)5.16.5 Cellsafe Biotech Recent Developments5.17 PacifiCord5.17.1 PacifiCord Profile5.17.2 PacifiCord Main Business and Companys Total Revenue5.17.3 PacifiCord Products, Services and Solutions5.17.4 PacifiCord Revenue (US$ Million) (2015-2020)5.17.5 PacifiCord Recent Developments5.18 Americord5.18.1 Americord Profile5.18.2 Americord Main Business and Companys Total Revenue5.18.3 Americord Products, Services and Solutions5.18.4 Americord Revenue (US$ Million) (2015-2020)5.18.5 Americord Recent Developments5.19 Krio5.19.1 Krio Profile5.19.2 Krio Main Business and Companys Total Revenue5.19.3 Krio Products, Services and Solutions5.19.4 Krio Revenue (US$ Million) (2015-2020)5.19.5 Krio Recent Developments5.20 Familycord5.20.1 Familycord Profile5.20.2 Familycord Main Business and Companys Total Revenue5.20.3 Familycord Products, Services and Solutions5.20.4 Familycord Revenue (US$ Million) (2015-2020)5.20.5 Familycord Recent Developments5.21 Cryo Stemcell5.21.1 Cryo Stemcell Profile5.21.2 Cryo Stemcell Main Business and Companys Total Revenue5.21.3 Cryo Stemcell Products, Services and Solutions5.21.4 Cryo Stemcell Revenue (US$ Million) (2015-2020)5.21.5 Cryo Stemcell Recent Developments5.22 Stemade Biotech5.22.1 Stemade Biotech Profile5.22.2 Stemade Biotech Main Business and Companys Total Revenue5.22.3 Stemade Biotech Products, Services and Solutions5.22.4 Stemade Biotech Revenue (US$ Million) (2015-2020)5.22.5 Stemade Biotech Recent Developments 6 North America Stem Cell Banking by Players and by Application6.1 North America Stem Cell Banking Market Size and Market Share by Players (2015-2020)6.2 North America Stem Cell Banking Market Size by Application (2015-2020) 7 Europe Stem Cell Banking by Players and by Application7.1 Europe Stem Cell Banking Market Size and Market Share by Players (2015-2020)7.2 Europe Stem Cell Banking Market Size by Application (2015-2020) 8 China Stem Cell Banking by Players and by Application8.1 China Stem Cell Banking Market Size and Market Share by Players (2015-2020)8.2 China Stem Cell Banking Market Size by Application (2015-2020) 9 Rest of Asia Pacific Stem Cell Banking by Players and by Application9.1 Rest of Asia Pacific Stem Cell Banking Market Size and Market Share by Players (2015-2020)9.2 Rest of Asia Pacific Stem Cell Banking Market Size by Application (2015-2020) 10 Latin America Stem Cell Banking by Players and by Application10.1 Latin America Stem Cell Banking Market Size and Market Share by Players (2015-2020)10.2 Latin America Stem Cell Banking Market Size by Application (2015-2020) 11 Middle East & Africa Stem Cell Banking by Players and by Application11.1 Middle East & Africa Stem Cell Banking Market Size and Market Share by Players (2015-2020)11.2 Middle East & Africa Stem Cell Banking Market Size by Application (2015-2020) 12 Stem Cell Banking Market Dynamics12.1 Industry Trends12.2 Market Drivers12.3 Market Challenges12.4 Porters Five Forces Analysis 13 Research Finding /Conclusion 14 Methodology and Data Source14.1 Methodology/Research Approach14.1.1 Research Programs/Design14.1.2 Market Size Estimation14.1.3 Market Breakdown and Data Triangulation14.2 Data Source14.2.1 Secondary Sources14.2.2 Primary Sources14.3 Disclaimer14.4 Author List

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
COVID-19 Impact on Stem Cell Banking Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 - Science...

Posted in Stem Cell Research | Comments Off on COVID-19 Impact on Stem Cell Banking Identify Which Types of Companies Could Potentially Benefit or Loose out From the Impact of COVID-19 – Science…

Key Provisions of the Legislature’s Internal Rules – The Joint Rules Part I – California Globe

Posted: April 8, 2020 at 10:45 am

Beyond the relevant provisions of the California Constitution (contained primarily in Article IV), as well as applicable sections of the California Government Code, the State Senate and State Assembly are governed by their Joint Rules, the Standing Rules of the Senate and the Standing Rules of the Assembly. This article provides a summary of the Joint Rules of the Senate and Assembly.

Joint Rules

The following is a summary of the Joint Rules with the corresponding rule number at the end of the explanatory sentence. Note that some Rule numbers do not exist.

Standing Committees Each house appoints standing committees based upon each houses own rules. (1)

Joint Meeting of Committees Whenever the same or like bill has been referred to both Senate and Assembly committees, the chairs shall arrange for a joint meeting to consider the bill. (3)

Effect of Adoption of Joint Rules Adopting Joint Rules for a special session does not modify or rescind the Joint Rules for any previous session. (3.5)

Definition of Word Bill Bill as used in the Joint Rules includes any constitutional amendment or resolution. (4)

Concurrent and Joint Resolutions Concurrent resolutions relate to matters to be treated by both houses, while joint resolutions relate to matters connected with the federal government. (5)

Resolutions Treated as Bills Concurrent and joint resolutions are generally treated as bills, with four exceptions, such as only one formal reading in each house. (6)

Title of Bill The title of every bill introduced must convey an accurate statement of the contents of the bill and indicate the scope of the act and the object to be accomplished. A mere reference to a code section by number is not deemed sufficient. (7)

Division of Bill Into Sections A bill amending more than one code section must contain a separate section for each code section amended. (8)

Digest of Bills Introduced A bill may not be introduced unless it has a cover attached by Legislative Counsel and is accompanied by a digest showing the changes in existing law that are proposed by the bill. Neither the Digest nor the bill can be altered. (8.5)

Digest of Bills Amended Whenever a bill is amended, the Senate Secretary or Assembly Chief Clerk must request Legislative Counsel to prepare an amended digest and have it printed on the bill first page of the bill as amended. Any material changes in the digest must be indicated. (8.6)

Errors in Digest If a material error in the digest is brought to the Legislative Counsels attention, a corrected digest is prepared and either the Assembly Speaker or Senate President pro Tempore can have a corrected version printed. (8.7)

Bills Amending Title 9 of the Government Code A bill that amends, adds or repeals any provision of Government Code Title 9 must notify the Senate Secretary or the Assembly Chief Clerk, who then delivers a copy of the bill to the FPPC. (8.8)

Bills Amending the California Stem Cell Research and Cures Act A bill that amends, adds or repeals any provision of the California Stem Cell Research and Cures Act must notify the Senate Secretary or the Assembly Chief Clerk, who then makes copies accessible in the Bill Room for the public and news media at least 14 days before passage. (8.9)

Bills Amending Section 6 of the Smaller Classes, Safer Schools and Financial Accountability Act A bill that amends, adds or repeals Education Code Section 47614 must notify the Senate Secretary or the Assembly Chief Clerk, who then makes copies accessible in the Bill Room for the public and news media at least 14 days before passage. (8.95)

Restrictions as to Amendments A substitute or amendment must related to the same subject as the original measure and an amendment is not in order when all that would be done to the bill is the addition of a coauthor, unless the Rules Committee grants prior approval. (9)

Changes in Existing Law to Be Marked by Author In a bill amending or repealing a code section, any new matter is underlined, and any matter to be omitted is with a horizontal line through the center. When printed, the new matter is in italics and the matter omitted is in strikeout. When an entire code, or an entire title, part, division, chapter, or article of a code is repealed, those sections are not set forth in the bill or amendment. (10)

Re-referral to Fiscal and Rules Committees A bill is re-referred to the fiscal committee of both houses when it would do any of the following: (1) Appropriate money; (2) Result in a substantial expenditure of state money; (3) Result in a substantial increase or loss of revenue to the state; (4) Result in substantial reduction of expenditures of state money by reducing, transferring, or eliminating any existing responsibilities of any state agency, program, or function. In addition, any concurrent and joint resolutions are re-referred to the fiscal committee of each house when they contemplate any action that would involve either (1) Any substantial expenditure of state money or (2) Any substantial loss of revenue to the state. This rule may be suspended with Rules Committee approval and a 2/3 vote of the house. (10.5)

Short Title A bill may not add a short title that names a current or former Member of the Legislature. (10.6)

Heading of Bills A bill or resolution may be authored only by a Member or committee of the house of origin. All others can be principal coauthors or coauthors. A bill may not indicate that it was introduced at the request of a state agency, officer or any other person. (10.7)

Consideration of Bills There must be a written request to consider and act upon a bill within 30 calendar days filed with the Senate Secretary or Assembly Chief Clerk. The Rules Committees determine whether there exists an urgent need for dispensing with the 30-day waiting period following introduction. If recommended, the house must adopt the authorizing resolution by majority vote. (10.8)

Printing of Amendments Any bill amended in either house must be immediately reprinted. The new matter is printed in italics and the matter omitted is in strikeout. If an amendment omits the entire contents of the bill, the matter omitted does not need to be reprinted. A brief statement will appear after the last line of the amended bill identifying the previous version of the bill that contains the complete text of the omitted matter. (11)

Manner of Printing Bills The State Printer must observe the directions of the Joint Rules Committee in printing all measures. (12)

Distribution of Legislative Publications Senate Secretary and Assembly Chief Clerk must order bills and legislative publications necessary for conducting business. No more than one copy of a bill or legislative publication is free to anyone, except Members, Legislative Counsel, and the nine constitutional officers, the courts, libraries, and the press. State Printer fixes the costs of bills and publications. The total number of each bill to be printed may not exceed 2500. (13)

Legislative Index Legislative Counsel provides for the periodic publication of a cumulate Legislative Index, which must include tables of sections affected by pending legislation. The State Printer must print the Index. (13.1)

Summary Digest Legislative Counsel must compile and prepare for publication of a summary digest of legislation passed at all sessions. It is a separate publication and is made available to the public at a price. (13.3)

Statutory Record Legislative Counsel prepares for publication a cumulative statutory record, which is printed by the State Printer. (13.5)

Printing of the Daily Journal The State Printer must print copies of the Daily Journal of each days proceedings. Also printed is a compilation at the end of session of all the journals in book form. (14)

What Shall Be Printed in the Daily Journal The Daily Journal of each house must include messages from the Governor and the other house, titles of all measures when introduced or acted upon, every vote taken and paper presented, and a true and accurate account of the houses proceedings. (15)

Chris Micheli is a lobbyist with Aprea & Micheli, as well as an Adjunct Professor of Law at the University of the Pacific McGeorge School of Law.

See original here:
Key Provisions of the Legislature's Internal Rules - The Joint Rules Part I - California Globe

Posted in Stem Cell Research | Comments Off on Key Provisions of the Legislature’s Internal Rules – The Joint Rules Part I – California Globe

Human Embryonic Stem Cell Assay Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

Posted: April 8, 2020 at 10:45 am

New Jersey, United States: Market Research Intellect has added a new research report titled, Human Embryonic Stem Cell Assay Market Professional Survey Report 2020 to its vast collection of research reports. The Human Embryonic Stem Cell Assay market is expected to grow positively for the next five years 2020-2026.

The Human Embryonic Stem Cell Assay market report studies past factors that helped the market to grow as well as, the ones hampering the market potential. This report also presents facts on historical data from 2011 to 2019 and forecasts until 2026, which makes it a valuable source of information for all the individuals and industries around the world. This report gives relevant market information in readily accessible documents with clearly presented graphs and statistics. This report also includes views of various industry executives, analysts, consultants, and marketing, sales, and product managers.

Key Players Mentioned in the Human Embryonic Stem Cell Assay Market Research Report:

Market Segment as follows:

The global Human Embryonic Stem Cell Assay Market report highly focuses on key industry players to identify the potential growth opportunities, along with the increased marketing activities is projected to accelerate market growth throughout the forecast period. Additionally, the market is expected to grow immensely throughout the forecast period owing to some primary factors fuelling the growth of this global market. Finally, the report provides detailed profile and data information analysis of leading Human Embryonic Stem Cell Assay company.

Human Embryonic Stem Cell Assay Market by Regional Segments:

The chapter on regional segmentation describes the regional aspects of the Human Embryonic Stem Cell Assay market. This chapter explains the regulatory framework that is expected to affect the entire market. It illuminates the political scenario of the market and anticipates its impact on the market for Human Embryonic Stem Cell Assay .

The Human Embryonic Stem Cell Assay Market research presents a study by combining primary as well as secondary research. The report gives insights on the key factors concerned with generating and limiting Human Embryonic Stem Cell Assay market growth. Additionally, the report also studies competitive developments, such as mergers and acquisitions, new partnerships, new contracts, and new product developments in the global Human Embryonic Stem Cell Assay market. The past trends and future prospects included in this report makes it highly comprehensible for the analysis of the market. Moreover, The latest trends, product portfolio, demographics, geographical segmentation, and regulatory framework of the Human Embryonic Stem Cell Assay market have also been included in the study.

Ask For Discount (Special Offer: Get 25% discount on this report) @ https://www.marketresearchintellect.com/ask-for-discount/?rid=203853&utm_source=SI&utm_medium=888

Table of Content

1 Introduction of Human Embryonic Stem Cell Assay Market1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Human Embryonic Stem Cell Assay Market Outlook4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Human Embryonic Stem Cell Assay Market, By Deployment Model5.1 Overview

6 Human Embryonic Stem Cell Assay Market, By Solution6.1 Overview

7 Human Embryonic Stem Cell Assay Market, By Vertical7.1 Overview

8 Human Embryonic Stem Cell Assay Market, By Geography8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Human Embryonic Stem Cell Assay Market Competitive Landscape9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix11.1 Related Research

Complete Report is Available @ https://www.marketresearchintellect.com/product/human-embryonic-stem-cell-assay-market-size-and-forecast/?utm_source=SI&utm_medium=888

We also offer customization on reports based on specific client requirement:

1-Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis of any market players.

3-Free 40 analyst hoursto cover any other data points

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080

Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

https://www.marktforschungsblogs.com/

Tags: Human Embryonic Stem Cell Assay Market Size, Human Embryonic Stem Cell Assay Market Growth, Human Embryonic Stem Cell Assay Market Forecast, Human Embryonic Stem Cell Assay Market Analysis, Human Embryonic Stem Cell Assay Market Trends, Human Embryonic Stem Cell Assay Market

Continue reading here:
Human Embryonic Stem Cell Assay Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 - Science In Me

Posted in Stem Cell Research | Comments Off on Human Embryonic Stem Cell Assay Market Size Analysis, Top Manufacturers, Shares, Growth Opportunities and Forecast to 2026 – Science In Me

Cancer Stem Cells (CSCs) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 – Science In Me

Posted: April 8, 2020 at 10:45 am

Cancer Stem Cells (CSCs) Market

DataIntelo, 08-04-2020: The research report on the Cancer Stem Cells (CSCs) Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data and compared it with the changing market situations. The report covers all the necessary information required by new entrants as well as the existing players to gain deeper insight.

Furthermore, the statistical survey in the report focuses on product specifications, costs, production capacities, marketing channels, and market players. Upstream raw materials, downstream demand analysis, and a list of end-user industries have been studied systematically, along with the suppliers in this market. The product flow and distribution channel have also been presented in this research report.

Get a PDF Copy of the Sample Report for Free @ https://dataintelo.com/request-sample/?reportId=116862

The Major Manufacturers Covered in this Report:JanssenQiagenAdvanced Cell DiagnosticsApoCellBiofluidicaClearbridge BiomedicsCytoTrackCelseeFluxionGilupiCynvenioOn-chipYZY BioBioViewCreatv MicroTechFluidigmIkonisysAdnaGenIVDiagnosticsMiltenyi BiotecAviva Biosciences CorporationScreenCellSilicon Biosystems

The Research Study Focuses on:

By Types:CellSearchOthers

By Applications:Breast Cancer Diagnosis and TreatmentProstate Cancer Diagnosis and TreatmentColorectal Cancer Diagnosis and TreatmentLung Cancer Diagnosis and TreatmentOther Cancers Diagnosis and Treatment

By Regions:

To get this report at incredible Discounts, visit @ https://dataintelo.com/ask-for-discount/?reportId=116862

The Cancer Stem Cells (CSCs) Market Report Consists of the Following Points:

Make an Inquiry of the Cancer Stem Cells (CSCs) Market Report @ https://dataintelo.com/enquiry-before-buying/?reportId=116862

In conclusion, the Cancer Stem Cells (CSCs) Market report is a reliable source for accessing the research data that is projected to exponentially accelerate your business. The report provides information such as economic scenarios, benefits, limits, trends, market growth rate, and figures. SWOT analysis is also incorporated in the report along with speculation attainability investigation and venture return investigation.

About DataIntelo:DATAINTELO has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info:Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://dataintelo.com

Excerpt from:
Cancer Stem Cells (CSCs) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 - Science In Me

Posted in Stem Cell Research | Comments Off on Cancer Stem Cells (CSCs) Market Size, Share & Trends Analysis Report By Product Types, And Applications Forecast To 2026 – Science In Me

Stem Cell Services Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2026 | Industry…

Posted: April 8, 2020 at 10:45 am

The Global Stem Cell Services Market analysis report published on IndustryGrowthInsights.com is a detailed study of market size, share and dynamics covered in XX pages and is an illustrative sample demonstrating market trends. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. It covers the entire market with an in-depth study on revenue growth and profitability. The report also delivers on key players along with strategic standpoint pertaining to price and promotion.

Get FREE Exclusive PDF Sample Copy of This Report: https://industrygrowthinsights.com/request-sample/?reportId=172092

The Global Stem Cell Services Market report entails a comprehensive database on future market estimation based on historical data analysis. It enables the clients with quantified data for current market perusal. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and regional analysis. Listed out are key players, major collaborations, merger & acquisitions along with upcoming and trending innovation. Business policies are reviewed from the techno-commercial perspective demonstrating better results. The report contains granular information & analysis pertaining to the Global Stem Cell Services Market size, share, growth, trends, segment and forecasts from 2020-2026.

With an all-round approach for data accumulation, the market scenarios comprise major players, cost and pricing operating in the specific geography/ies. Statistical surveying used are SWOT analysis, PESTLE analysis, predictive analysis, and real-time analytics. Graphs are clearly used to support the data format for clear understanding of facts and figures.

Customize Report and Inquiry for The Stem Cell Services Market Report: https://industrygrowthinsights.com/enquiry-before-buying/?reportId=172092

Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Primary research, interviews, news sources and information booths have made the report precise having valuable data. Secondary research techniques add more in clear and concise understanding with regards to placing of data in the report.

The report segments the Global Stem Cell Services Market as:Global Stem Cell Services Market Size & Share, by Regions

Global Stem Cell Services Market Size & Share, by ProductsCustomize ServiceStem Cell DifferentiationAssay DevelopmentScreeningOthersStem Cell Service

Global Stem Cell Services Market Size & Share, ApplicationsHospitalResearch InstituteOthers

Key PlayersParagon BioservicesAPEX BiologixVcanBioCryo-cellCrioestaminalLifeCellViaCordPepro TechHealth BabyStem Cell Service

Avail the Discount on this Report @ https://industrygrowthinsights.com/ask-for-discount/?reportId=172092

IndustryGrowthInsights offers attractive discounts on customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

About IndustryGrowthInsights:INDUSTRYGROWTHINSIGHTS has set its benchmark in the market research industry by providing syndicated and customized research report to the clients. The database of the company is updated on a daily basis to prompt the clients with the latest trends and in-depth analysis of the industry. Our pool of database contains various industry verticals that include: IT & Telecom, Food Beverage, Automotive, Healthcare, Chemicals and Energy, Consumer foods, Food and beverages, and many more. Each and every report goes through the proper research methodology, validated from the professionals and analysts to ensure the eminent quality reports.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario, CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://IndustryGrowthInsights.com

Visit link:
Stem Cell Services Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2026 | Industry...

Posted in Stem Cell Research | Comments Off on Stem Cell Services Market 2020 Size By Product Types, End-Users, Regional Outlook, Growth Potential, Price Trends And Forecast To 2026 | Industry…

Page 1,069«..1020..1,0681,0691,0701,071..1,0801,090..»